Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas
Abstract
BACKGROUND.: Single‐agent gemcitabine and vinorelbine have activity in treatment of patients with soft‐tissue sarcomas. The combination of gemcitabine plus vinorelbine has activity against several forms of metastatic carcinoma with acceptable toxicity. This study evaluated the efficacy and tolerability of gemcitabine plus vinorelbine in advanced soft‐tissue sarcoma.METHODS.: A single academic center performed this phase II trial. Eligible patients had unresectable or metastatic soft‐tissue sarcomas, Eastern Cooperative Group performance status of 0–2, adequate organ function, and ≤1 prior regimen. Gemcitabine 800 mg/m2 was given over 90 minutes on Days 1 and 8 of a 21‐day cycle after administration of vinorelbine 25 mg/m2. Dosing schedule was modified for toxicity (doses constant but administered on Days 1 and 15 of a 28‐day cycle). Dose reductions were allowed if unacceptable toxicities recurred.RESULTS.: The study accrued 40 patients, and 248 dosing cycles were administered (range, 1–32). No treatment‐related deaths occurred. Of 9 episodes of grade 4 toxicities, 8 were hematologic. Of 38 episodes of grade 3 toxicity, 24 were hematologic. Clinical benefit was seen in 25% of patients and was defined as complete response (CR), partial response (PR), or stable disease (SD) at >4 months. There has been 1 CR lasting >1 year in a patient with high‐grade pleomorphic spindle‐cell sarcoma.CONCLUSIONS.: Gemcitabine given by a fixed‐dose rate of infusion combined with vinorelbine was associated with clinically meaningful rates of disease control in patients with advanced soft‐tissue sarcoma. Toxicity was acceptable. This study contributed to data that have supported the administration of fixed‐dose rate gemcitabine‐based drug regimens in soft‐tissue sarcomas. Cancer 2007. © 2007 American Cancer Society.Keywords
This publication has 25 references indexed in Scilit:
- Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treament With Gemcitabine Followed by Docetaxel in the Treatment of SarcomaJournal of Clinical Oncology, 2004
- Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2003
- Phase II trial of gemcitabine in patients with advanced sarcomas (E1797)Cancer, 2003
- Phase II Trial of Biweekly Administration of Vinorelbine and Gemcitabine in Pretreated Advanced Breast CancerJournal of Clinical Oncology, 2002
- Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinomaCancer, 2001
- Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimensEuropean Journal of Cancer, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II studyCancer Chemotherapy and Pharmacology, 2000
- Doxorubicin in relapsed soft tissue sarcoma: Justification of phase II evaluation of new drugs in this diseaseEuropean Journal of Cancer and Clinical Oncology, 1990
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989